Oncology Early Phase / Multiple Disease Site Hematologic Malignancies Early Phase Team Leukemia AML Relapsed/Refractory Exhausted all SOC options
Categories
Protocols
JNJ-75276617ALE1001 Phase I/II OPEN TO ACCRUAL
A Phase 1/2, First-in-Human Study of the Menin-KMT2A (MLL1) Inhibitor Bleximenib in Participants with Acute Leukemia